Cargando…
Effectiveness and cost-effectiveness of RSV infant and maternal immunization programs: A case study of Nunavik, Canada
BACKGROUND: Despite passive immunization with palivizumab to select high-risk children under two years of age, the health and economic burden of respiratory syncytial virus (RSV) remains substantial. We evaluated the effectiveness and cost-effectiveness of immunization programs with new generations...
Autores principales: | Nourbakhsh, Shokoofeh, Shoukat, Affan, Zhang, Kevin, Poliquin, Guillaume, Halperin, Donna, Sheffield, Holden, Halperin, Scott A., Langley, Joanne M., Moghadas, Seyed M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479643/ https://www.ncbi.nlm.nih.gov/pubmed/34622186 http://dx.doi.org/10.1016/j.eclinm.2021.101141 |
Ejemplares similares
-
Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study
por: Shoukat, Affan, et al.
Publicado: (2023) -
Cost-effectiveness of Prophylactic Zika Virus Vaccine in the Americas
por: Shoukat, Affan, et al.
Publicado: (2019) -
Cost-effectiveness of a potential Zika vaccine candidate: a case study for Colombia
por: Shoukat, Affan, et al.
Publicado: (2018) -
Routine saliva testing for the identification of silent coronavirus disease 2019 (COVID-19) in healthcare workers
por: Zhang, Kevin, et al.
Publicado: (2021) -
Routine saliva testing for the identification of silent COVID-19 infections in healthcare workers
por: Zhang, Kevin, et al.
Publicado: (2020)